107 related articles for article (PubMed ID: 17387689)
41. Pitfalls associated with the use of Thioflavin-T to monitor anti-fibrillogenic activity.
Coelho-Cerqueira E; Pinheiro AS; Follmer C
Bioorg Med Chem Lett; 2014 Jul; 24(14):3194-8. PubMed ID: 24835632
[TBL] [Abstract][Full Text] [Related]
42. Real-time analysis of amyloid fibril formation of alpha-synuclein using a fibrillation-state-specific fluorescent probe of JC-1.
Lee JH; Lee IH; Choe YJ; Kang S; Kim HY; Gai WP; Hahn JS; Paik SR
Biochem J; 2009 Mar; 418(2):311-23. PubMed ID: 19007333
[TBL] [Abstract][Full Text] [Related]
43. Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment.
Kim HJ; Chatani E; Goto Y; Paik SR
J Microbiol Biotechnol; 2007 Dec; 17(12):2027-32. PubMed ID: 18167451
[TBL] [Abstract][Full Text] [Related]
44. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein.
Rekas A; Lo V; Gadd GE; Cappai R; Yun SI
Macromol Biosci; 2009 Mar; 9(3):230-8. PubMed ID: 19116892
[TBL] [Abstract][Full Text] [Related]
45. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein.
Brandt I; Gérard M; Sergeant K; Devreese B; Baekelandt V; Augustyns K; Scharpé S; Engelborghs Y; Lambeir AM
Peptides; 2008 Sep; 29(9):1472-8. PubMed ID: 18571285
[TBL] [Abstract][Full Text] [Related]
46. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
47. Characterization of fibrillation process of alpha-synuclein at the initial stage.
Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
[TBL] [Abstract][Full Text] [Related]
48. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study.
Bharathi ; Indi SS; Rao KS
Neurosci Lett; 2007 Sep; 424(2):78-82. PubMed ID: 17714865
[TBL] [Abstract][Full Text] [Related]
49. Mulberry leaf extract prevents amyloid beta-peptide fibril formation and neurotoxicity.
Niidome T; Takahashi K; Goto Y; Goh S; Tanaka N; Kamei K; Ichida M; Hara S; Akaike A; Kihara T; Sugimoto H
Neuroreport; 2007 May; 18(8):813-6. PubMed ID: 17471072
[TBL] [Abstract][Full Text] [Related]
50. Curcumin inhibits aggregation of alpha-synuclein.
Pandey N; Strider J; Nolan WC; Yan SX; Galvin JE
Acta Neuropathol; 2008 Apr; 115(4):479-89. PubMed ID: 18189141
[TBL] [Abstract][Full Text] [Related]
51. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
[TBL] [Abstract][Full Text] [Related]
52. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
[TBL] [Abstract][Full Text] [Related]
53. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease.
Zhao DL; Zou LB; Zhou LF; Zhu P; Zhu HB
Acta Pharmacol Sin; 2007 May; 28(5):616-26. PubMed ID: 17439717
[TBL] [Abstract][Full Text] [Related]
54. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
Stefanova N; Poewe W; Wenning GK
Exp Neurol; 2008 Apr; 210(2):421-7. PubMed ID: 18222424
[TBL] [Abstract][Full Text] [Related]
55. Multiparametric fluorescence detection of early stages in the amyloid protein aggregation of pyrene-labeled alpha-synuclein.
Thirunavukkuarasu S; Jares-Erijman EA; Jovin TM
J Mol Biol; 2008 May; 378(5):1064-73. PubMed ID: 18433772
[TBL] [Abstract][Full Text] [Related]
56. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
Sass MB; Lorenz AN; Green RL; Coleman RA
J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
[TBL] [Abstract][Full Text] [Related]
57. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
Uversky VN
J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
[TBL] [Abstract][Full Text] [Related]
58. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
59. Helical alpha-synuclein forms highly conductive ion channels.
Zakharov SD; Hulleman JD; Dutseva EA; Antonenko YN; Rochet JC; Cramer WA
Biochemistry; 2007 Dec; 46(50):14369-79. PubMed ID: 18031063
[TBL] [Abstract][Full Text] [Related]
60. Tilted properties of the 67-78 fragment of alpha-synuclein are responsible for membrane destabilization and neurotoxicity.
Crowet JM; Lins L; Dupiereux I; Elmoualija B; Lorin A; Charloteaux B; Stroobant V; Heinen E; Brasseur R
Proteins; 2007 Sep; 68(4):936-47. PubMed ID: 17554782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
